2016-04-28 16:02:47 UTC

Pancreatic Cancer

Chicago, IL.

Duration

18:57

About

Review of treatments Pancreatic Cancer:

Download the session audio:

MP3 File

Download the PowerPoint presentation:

PPT File

About the Instructors

Andrew D. Rhim, MD

Andrew D. Rhim MD is Assistant Professor of Internal Medicine-Gastroenterology at the University of Michigan Medical School. Prior to his recruitment July 2013, Dr. Rhim was the William Osler MD Fellow in Medicine and Instructor of Medicine at the Perleman School of Medicine at the University of Pennsylvania. Dr. Rhim completed his medical training, residency in internal medicine, clinical fellowship and research fellowship in genetics at the University of Pennsylvania. Dr. Rhim's research is focused on understanding the key molecular and cellular events that occur when precancerous lesions transform into cancer. By understanding this critical window of time, he hopes to develop new ways to diagnose and treat the earliest stages of cancer, before it can be detected using current clinical testing. Dr. Rhim has chosen to focus his efforts on pancreatic cancer and pancreatic cyst disease given the poor prognosis associated with these diseases. Dr. Rhim uses a variety of approaches and systems in his research, including a novel genetically engineered mouse model of pancreatic cancer and microfluidic technology. Dr. Rhim's work has been recognized in numerous ways. Dr. Rhim has received numerous awards, including the Career Development Awards from the American Association for Cancer Research, Pancreatic Cancer Action Network, Department of Defense and the American Gastroenterological Association, the Caroline Craig and Damian Augustyn Award in Digestive Cancer, the Gregory Gurtner Memorial Professorship, Frank Brooks Memorial Research Award and the Betsy Cohen Award in Cancer Research. His research program is currently funded by eight federal and private foundation grants. Dr. Rhim's clinical interests and expertise center on stratifying and managing risk for cancer in patients susceptible to pancreatic cancer, including patients with pancreatic cystic lesions and patients with particularly strong family histories for pancreatic cancer. He currently sees patients in the Multidisciplinary Pancreatic Disease Program in the University of Michigan Comprehensive Cancer Center.

More on Pancreatic Cancer

Stepped-Up Moves to Understand, Diagnose IBD-Related Autoimmune Pancreatitis

Oct. 12, 2017

Possible genetic overlap; concurrence shown to affect clinical course, pancreatic cancer risk.

Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis

Oct. 11, 2017

We found that low-risk IPMNs have almost 8% chance of progressing to pancreatic cancer within 10 years.

Congressional Committees Approve Increase for NIH Funding

Sept. 13, 2017

Senate bill includes funding for gastrointestinal disorders and cancers.